Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 208

1.

Response to Dabrafenib and Trametinib of a Patient with Metaplastic Breast Carcinoma Harboring a BRAF V600E Mutation.

Seo T, Noguchi E, Yoshida M, Mori T, Tanioka M, Sudo K, Shimomura A, Yonemori K, Fujiwara Y, Tamura K.

Case Rep Oncol Med. 2020 Mar 6;2020:2518383. doi: 10.1155/2020/2518383. eCollection 2020.

2.

Long-term survival analysis of addition of carboplatin to neoadjuvant chemotherapy in HER2-negative breast cancer.

Iwase M, Ando M, Aogi K, Aruga T, Inoue K, Shimomura A, Tokunaga E, Masuda N, Yamauchi H, Yamashita T, Iwata H.

Breast Cancer Res Treat. 2020 Apr;180(3):687-694. doi: 10.1007/s10549-020-05580-y. Epub 2020 Mar 5.

PMID:
32140811
3.

Peripheral neuropathy from paclitaxel: risk prediction by serum microRNAs.

Noda-Narita S, Shimomura A, Tanabe Y, Kawauchi J, Matsuzaki J, Takizawa S, Aoki Y, Shimizu C, Tamura K, Ochiya T.

BMJ Support Palliat Care. 2020 Jan 14. pii: bmjspcare-2019-001900. doi: 10.1136/bmjspcare-2019-001900. [Epub ahead of print]

PMID:
31937590
4.

[Ⅰ.Detecting Early Breast Cancer by Serum MicroRNA].

Shimomura A, Ochiya T.

Gan To Kagaku Ryoho. 2019 Dec;46(12):1837-1840. Japanese. No abstract available.

PMID:
31879399
5.

First-in-human phase I study of E7090, a novel selective fibroblast growth factor receptor inhibitor, in patients with advanced solid tumors.

Koyama T, Shimizu T, Iwasa S, Fujiwara Y, Kondo S, Kitano S, Yonemori K, Shimomura A, Iizumi S, Sasaki T, Furuse J, Yamamoto N.

Cancer Sci. 2020 Feb;111(2):571-579. doi: 10.1111/cas.14265.

6.

Improved survival among patients enrolled in oncology phase 1 trials in recent decades.

Ebata T, Shimizu T, Koyama T, Shimomura A, Iwasa S, Kondo S, Kitano S, Yonemori K, Fujiwara Y, Yamamoto N.

Cancer Chemother Pharmacol. 2020 Feb;85(2):449-459. doi: 10.1007/s00280-019-03992-2. Epub 2019 Nov 19.

PMID:
31745590
7.

Gender Differences in Program Factors Important to Applicants When Evaluating Orthopaedic Surgery Residency Programs.

Kroin E, Garbarski D, Shimomura A, Romano J, Schiff A, Wu K.

J Grad Med Educ. 2019 Oct;11(5):565-569. doi: 10.4300/JGME-D-18-01078.1.

PMID:
31636827
8.

[Ifosfamide and Paclitaxel for Recurrent or Metastatic Uterine Carcinosarcoma].

Ohtake Y, Sudo K, Kojima Y, Seo T, Okuma H, Nishikawa T, Uno M, Uehara T, Ishikawa M, Tanioka M, Noguchi E, Shimomura A, Yonemori K, Kato T, Fujiwara Y, Tamura K.

Gan To Kagaku Ryoho. 2019 Oct;46(10):1525-1529. Japanese.

PMID:
31631133
9.

Brain metastasis-related microRNAs in patients with advanced breast cancer.

Sato J, Shimomura A, Kawauchi J, Matsuzaki J, Yamamoto Y, Takizawa S, Sakamoto H, Ohno M, Narita Y, Ochiya T, Tamura K.

PLoS One. 2019 Oct 11;14(10):e0221538. doi: 10.1371/journal.pone.0221538. eCollection 2019.

10.

Serum microRNA-based prediction of responsiveness to eribulin in metastatic breast cancer.

Satomi-Tsushita N, Shimomura A, Matsuzaki J, Yamamoto Y, Kawauchi J, Takizawa S, Aoki Y, Sakamoto H, Kato K, Shimizu C, Ochiya T, Tamura K.

PLoS One. 2019 Sep 4;14(9):e0222024. doi: 10.1371/journal.pone.0222024. eCollection 2019.

11.

Gene Alterations in Triple-Negative Breast Cancer Patients in a Phase I/II Study of Eribulin and Olaparib Combination Therapy.

Shimomura A, Yonemori K, Yoshida M, Yoshida T, Yasojima H, Masuda N, Aogi K, Takahashi M, Naito Y, Shimizu S, Nakamura R, Hamada A, Michimae H, Hashimoto J, Yamamoto H, Kawachi A, Shimizu C, Fujiwara Y, Tamura K.

Transl Oncol. 2019 Oct;12(10):1386-1394. doi: 10.1016/j.tranon.2019.07.013. Epub 2019 Aug 2.

12.

Genetic manipulation of autonomic nerve fiber innervation and activity and its effect on breast cancer progression.

Kamiya A, Hayama Y, Kato S, Shimomura A, Shimomura T, Irie K, Kaneko R, Yanagawa Y, Kobayashi K, Ochiya T.

Nat Neurosci. 2019 Aug;22(8):1289-1305. doi: 10.1038/s41593-019-0430-3. Epub 2019 Jul 8.

PMID:
31285612
13.

Phase I study of the indoleamine 2,3-dioxygenase 1 inhibitor navoximod (GDC-0919) as monotherapy and in combination with the PD-L1 inhibitor atezolizumab in Japanese patients with advanced solid tumours.

Ebata T, Shimizu T, Fujiwara Y, Tamura K, Kondo S, Iwasa S, Yonemori K, Shimomura A, Kitano S, Koyama T, Sato N, Nakai K, Inatani M, Yamamoto N.

Invest New Drugs. 2020 Apr;38(2):468-477. doi: 10.1007/s10637-019-00787-3. Epub 2019 May 24.

14.

Bone marrow examination in patients with Ewing sarcoma/peripheral primitive neuroectodermal tumor without metastasis based on 18F-fluorodeoxyglucose positron emission tomography/computed tomography.

Inagaki C, Shimoi T, Sumiyoshi Okuma H, Kawachi A, Sudo K, Shimomura A, Noguchi E, Kodaira M, Yunokawa M, Yonemori K, Shimizu C, Arakawa A, Ogawa C, Yoshida A, Fujiwara Y, Tamura K.

Med Oncol. 2019 May 18;36(7):58. doi: 10.1007/s12032-019-1279-8.

PMID:
31104192
15.

Effects of bowel preparation on the human gut microbiome and metabolome.

Nagata N, Tohya M, Fukuda S, Suda W, Nishijima S, Takeuchi F, Ohsugi M, Tsujimoto T, Nakamura T, Shimomura A, Yanagisawa N, Hisada Y, Watanabe K, Imbe K, Akiyama J, Mizokami M, Miyoshi-Akiyama T, Uemura N, Hattori M.

Sci Rep. 2019 Mar 11;9(1):4042. doi: 10.1038/s41598-019-40182-9.

16.

Next endoscopic approach for acute lower gastrointestinal bleeding without an identified source on colonoscopy: upper or capsule endoscopy?

Aoki T, Nagata N, Yamada A, Shimbo T, Matsushita Y, Shimomura A, Kobayashi S, Moriyasu S, Niikura R, Sakurai T, Hirata Y, Akiyama J, Uemura N, Koike K.

Endosc Int Open. 2019 Mar;7(3):E337-E346. doi: 10.1055/a-0824-6647. Epub 2019 Feb 28.

17.

Feasibility and utility of a panel testing for 114 cancer-associated genes in a clinical setting: A hospital-based study.

Sunami K, Ichikawa H, Kubo T, Kato M, Fujiwara Y, Shimomura A, Koyama T, Kakishima H, Kitami M, Matsushita H, Furukawa E, Narushima D, Nagai M, Taniguchi H, Motoi N, Sekine S, Maeshima A, Mori T, Watanabe R, Yoshida M, Yoshida A, Yoshida H, Satomi K, Sukeda A, Hashimoto T, Shimizu T, Iwasa S, Yonemori K, Kato K, Morizane C, Ogawa C, Tanabe N, Sugano K, Hiraoka N, Tamura K, Yoshida T, Fujiwara Y, Ochiai A, Yamamoto N, Kohno T.

Cancer Sci. 2019 Apr;110(4):1480-1490. doi: 10.1111/cas.13969. Epub 2019 Apr 2.

18.

Comparison of the efficacy of trastuzumab emtansine between patients with metastatic human epidermal growth factor receptor 2-positive breast cancers previously treated with combination trastuzumab and pertuzumab and with trastuzumab only in Japanese population.

Noda-Narita S, Shimomura A, Kawachi A, Sumiyoshi-Okuma H, Sudo K, Shimoi T, Noguchi E, Yonemori K, Shimizu C, Fujiwara Y, Tamura K.

Breast Cancer. 2019 Jul;26(4):492-498. doi: 10.1007/s12282-019-00949-4. Epub 2019 Feb 8.

19.

The Incidence of Nonmalignant Diseases among Patients with Suspected Carcinoma of Unknown Primary Site.

Sato J, Shimoi T, Shimomura A, Noguchi E, Kodaira M, Yunokawa M, Yonemori K, Shimizu C, Fujiwara Y, Yoshida M, Tamura K.

Intern Med. 2019 May 15;58(10):1423-1428. doi: 10.2169/internalmedicine.1118-18. Epub 2019 Feb 1.

20.

Eradication therapy for Helicobacter pylori infection improves nutrition status in Japanese hemodialysis patients: a pilot study.

Ichikawa H, Sugimoto M, Sakao Y, Sahara S, Ohashi N, Sano K, Tadokoro S, Azekura H, Shimomura A, Yamashita F, Sugiyama D, Fukuta K, Furuta T, Kato A, Sugimoto K, Yasuda H.

J Clin Biochem Nutr. 2019 Jan;64(1):91-95. doi: 10.3164/jcbn.18-61. Epub 2018 Oct 2.

21.

A phase I/II trial of olaparib tablet in combination with eribulin in Japanese patients with advanced or metastatic triple-negative breast cancer previously treated with anthracyclines and taxanes.

Yonemori K, Shimomura A, Yasojima H, Masuda N, Aogi K, Takahashi M, Naito Y, Shimizu S, Nakamura R, Hashimoto J, Yamamoto H, Hirakawa A, Michimae H, Hamada A, Yoshida T, Sukigara T, Tamura K, Fujiwara Y.

Eur J Cancer. 2019 Mar;109:84-91. doi: 10.1016/j.ejca.2018.11.014. Epub 2019 Jan 28.

PMID:
30703739
22.

First-in-Human Phase I Study of an Oral HSP90 Inhibitor, TAS-116, in Patients with Advanced Solid Tumors.

Shimomura A, Yamamoto N, Kondo S, Fujiwara Y, Suzuki S, Yanagitani N, Horiike A, Kitazono S, Ohyanagi F, Doi T, Kuboki Y, Kawazoe A, Shitara K, Ohno I, Banerji U, Sundar R, Ohkubo S, Calleja EM, Nishio M.

Mol Cancer Ther. 2019 Mar;18(3):531-540. doi: 10.1158/1535-7163.MCT-18-0831. Epub 2019 Jan 24.

23.

A quality assurance for respiratory gated proton irradiation with range modulation wheel.

Yasui K, Shimomura A, Toshito T, Tanaka K, Ueki K, Muramatsu R, Katsurada M, Hayashi N, Ogino H.

J Appl Clin Med Phys. 2019 Jan;20(1):258-264. doi: 10.1002/acm2.12526. Epub 2018 Dec 30.

24.

Serum miRNA-based Prediction of Axillary Lymph Node Metastasis in Breast Cancer.

Shiino S, Matsuzaki J, Shimomura A, Kawauchi J, Takizawa S, Sakamoto H, Aoki Y, Yoshida M, Tamura K, Kato K, Kinoshita T, Kitagawa Y, Ochiya T.

Clin Cancer Res. 2019 Mar 15;25(6):1817-1827. doi: 10.1158/1078-0432.CCR-18-1414. Epub 2018 Nov 27.

25.

Analysis of interference fringes based on three circularly polarized beams targeted for birefringence distribution measurements.

Shimomura A, Fukuda T, Emoto A.

Appl Opt. 2018 Sep 1;57(25):7318-7324. doi: 10.1364/AO.57.007318.

PMID:
30182994
26.

<Editors' Choice> Practice management for elderly patients with breast cancer; Findings from a survey by the Japan Breast Cancer Study Group.

Sawaki M, Tamura K, Shimomura A, Taki Y, Nagashima F, Iwata H.

Nagoya J Med Sci. 2018 May;80(2):217-226. doi: 10.18999/nagjms.80.2.217.

27.

PIK3CA mutation profiling in patients with breast cancer, using a highly sensitive detection system.

Shimoi T, Hamada A, Yamagishi M, Hirai M, Yoshida M, Nishikawa T, Sudo K, Shimomura A, Noguchi E, Yunokawa M, Yonemori K, Shimizu C, Kinoshita T, Fukuda T, Fujiwara Y, Tamura K.

Cancer Sci. 2018 Aug;109(8):2558-2566. doi: 10.1111/cas.13696. Epub 2018 Jul 28.

28.

Efficacy of capecitabine in patients with locally advanced or metastatic breast cancer with or without prior treatment with fluoropyrimidine: a retrospective study.

Iizumi S, Shimomura A, Shimoi T, Sudo K, Noguchi E, Yonemori K, Shimizu C, Fujiwara Y, Tamura K.

Cancer Chemother Pharmacol. 2018 Aug;82(2):275-283. doi: 10.1007/s00280-018-3617-5. Epub 2018 Jun 5.

29.

High and low estimated glomerular filtration rates are associated with adverse outcomes in patients undergoing surgery for gastrointestinal malignancies.

Ui T, Obi Y, Shimomura A, Lefor AK, Fazl Alizadeh R, Said H, Nguyen NT, Stamos MJ, Kalantar-Zadeh K, Sata N, Ichii H.

Nephrol Dial Transplant. 2019 May 1;34(5):810-818. doi: 10.1093/ndt/gfy108.

PMID:
29718365
30.

Protein carbamylation exacerbates vascular calcification.

Mori D, Matsui I, Shimomura A, Hashimoto N, Matsumoto A, Shimada K, Yamaguchi S, Oka T, Kubota K, Yonemoto S, Sakaguchi Y, Takahashi A, Shintani Y, Takashima S, Takabatake Y, Hamano T, Isaka Y.

Kidney Int. 2018 Jul;94(1):72-90. doi: 10.1016/j.kint.2018.01.033. Epub 2018 Apr 30.

PMID:
29716796
31.

Relevance of the hippocampal endoplasmic reticulum stress response in a mouse model of chronic kidney disease.

Kosuge Y, Osada N, Shimomura A, Miyagishi H, Wada T, Ishige K, Shimba S, Ito Y.

Neurosci Lett. 2018 Jun 11;677:26-31. doi: 10.1016/j.neulet.2018.04.021. Epub 2018 Apr 20.

PMID:
29680250
32.

Efficacy and Safety of Pazopanib for Recurrent or Metastatic Solitary Fibrous Tumor.

Ebata T, Shimoi T, Bun S, Miyake M, Yoshida A, Shimomura A, Noguchi E, Yonemori K, Shimizu C, Fujiwara Y, Narita Y, Tamura K.

Oncology. 2018;94(6):340-344. doi: 10.1159/000486623. Epub 2018 Apr 3.

PMID:
29614488
33.

Phase I study of taselisib in Japanese patients with advanced solid tumors or hormone receptor-positive advanced breast cancer.

Tamura K, Kodaira M, Shimizu C, Yonemori K, Yunokawa M, Shimomura A, Kobayashi T, Nakano K, Tomomatsu J, Ito Y, Tanaka J, Kuriki H, Gu Z, Takahashi S.

Cancer Sci. 2018 May;109(5):1592-1601. doi: 10.1111/cas.13561. Epub 2018 Mar 31.

34.

Gene aberration profile of tumors of adolescent and young adult females.

Kanke Y, Shimomura A, Saito M, Honda T, Shiraishi K, Shimada Y, Watanabe R, Yoshida H, Yoshida M, Shimizu C, Takahashi K, Totsuka H, Ogiwara H, Hirose S, Kono K, Tamura K, Okamoto A, Kinoshita T, Kato T, Kohno T.

Oncotarget. 2017 Dec 29;9(5):6228-6237. doi: 10.18632/oncotarget.23765. eCollection 2018 Jan 19.

35.

LATS2 promoter hypermethylation and its effect on gene expression in human breast cancer.

Matsui S, Kagara N, Mishima C, Naoi Y, Shimoda M, Shimomura A, Shimazu K, Kim SJ, Noguchi S.

Oncol Lett. 2018 Feb;15(2):2595-2603. doi: 10.3892/ol.2017.7535. Epub 2017 Dec 6.

36.

Prognostic impact of presumed breast or ovarian cancer among patients with unfavorable-subset cancer of unknown primary site.

Kodaira M, Yonemori K, Shimoi T, Yoshida A, Yoshida M, Kitano A, Shimomura A, Yunokawa M, Shimizu C, Takiguchi Y, Fujiwara Y, Tamura K.

BMC Cancer. 2018 Feb 13;18(1):176. doi: 10.1186/s12885-018-4092-4.

37.

[Local Control of Advanced Breast Cancer with Giant Ulcer].

Inoue T, Shimomura A, Sugimoto T, Wakamiya S, Chou U, Fujiwara A, Uchikoshi F, Watanabe T, Kitamura N.

Gan To Kagaku Ryoho. 2017 Nov;44(12):1062-1064. Japanese.

PMID:
29394534
38.

Endoglin (CD105) and SMAD4 regulate spheroid formation and the suppression of the invasive ability of human pancreatic cancer cells.

Kokaji E, Shimomura A, Minamisaka T, Nakajima T, Miwa S, Hatta H, Nishida T, Kiya C, Imura J.

Int J Oncol. 2018 Mar;52(3):892-900. doi: 10.3892/ijo.2018.4262. Epub 2018 Feb 1.

PMID:
29393426
39.

Symptom management: the utility of regional cooling for hand-foot syndrome induced by pegylated liposomal doxorubicin in ovarian cancer.

Bun S, Yunokawa M, Tamaki Y, Shimomura A, Shimoi T, Kodaira M, Shimizu C, Yonemori K, Fujiwara Y, Makino Y, Terakado H, Tamura K.

Support Care Cancer. 2018 Jul;26(7):2161-2166. doi: 10.1007/s00520-018-4054-z. Epub 2018 Jan 25.

PMID:
29372396
40.

The histone demethylase LSD1 regulates inner ear progenitor differentiation through interactions with Pax2 and the NuRD repressor complex.

Patel D, Shimomura A, Majumdar S, Holley MC, Hashino E.

PLoS One. 2018 Jan 25;13(1):e0191689. doi: 10.1371/journal.pone.0191689. eCollection 2018.

41.

TERT promoter hotspot mutations in breast cancer.

Shimoi T, Yoshida M, Kitamura Y, Yoshino T, Kawachi A, Shimomura A, Noguchi E, Yunokawa M, Yonemori K, Shimizu C, Kinoshita T, Ichimura K, Fukuda T, Fujiwara Y, Tamura K.

Breast Cancer. 2018 May;25(3):292-296. doi: 10.1007/s12282-017-0825-5. Epub 2017 Dec 8.

42.

New splicing variants of mitochondrial Rho GTPase-1 (Miro1) transport peroxisomes.

Okumoto K, Ono T, Toyama R, Shimomura A, Nagata A, Fujiki Y.

J Cell Biol. 2018 Feb 5;217(2):619-633. doi: 10.1083/jcb.201708122. Epub 2017 Dec 8.

43.

Efficacy and safety of eribulin in patients with locally advanced or metastatic breast cancer not meeting trial eligibility criteria: a retrospective study.

Iizumi S, Shimoi T, Tsushita N, Bun S, Shimomura A, Noguchi E, Kodaira M, Yunokawa M, Yonemori K, Shimizu C, Fujiwara Y, Tamura K.

BMC Cancer. 2017 Dec 4;17(1):819. doi: 10.1186/s12885-017-3846-8.

44.

Evaluation of dosimetric advantages of using patient-specific aperture system with intensity-modulated proton therapy for the shallow depth tumor.

Yasui K, Toshito T, Omachi C, Hayashi K, Tanaka K, Asai K, Shimomura A, Muramatsu R, Hayashi N.

J Appl Clin Med Phys. 2018 Jan;19(1):132-137. doi: 10.1002/acm2.12231. Epub 2017 Nov 27.

45.

A case of heavily pretreated metastatic cardiac angiosarcoma treated successfully using eribulin.

Inagaki C, Shimoi T, Okuma H, Kitano A, Shimomura A, Noguchi E, Kodaira M, Yunokawa M, Yonemori K, Shimizu C, Yoshida A, Fujiwara Y, Tamura K.

Anticancer Drugs. 2018 Jan;29(1):97-101. doi: 10.1097/CAD.0000000000000558.

PMID:
29176397
46.

The Prognostic Impact of the Pathological Response to Neoadjuvant Dose-Dense Therapy for Ovarian Carcinoma.

Ebata T, Yunokawa M, Yoshida H, Bun S, Shimoi T, Shimomura A, Kodaira M, Yonemori K, Shimizu C, Fujiwara Y, Kato T, Tamura K.

Int J Gynecol Cancer. 2017 Nov;27(9):1850-1855. doi: 10.1097/IGC.0000000000001107.

PMID:
29040183
47.

Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study.

Doi T, Shitara K, Naito Y, Shimomura A, Fujiwara Y, Yonemori K, Shimizu C, Shimoi T, Kuboki Y, Matsubara N, Kitano A, Jikoh T, Lee C, Fujisaki Y, Ogitani Y, Yver A, Tamura K.

Lancet Oncol. 2017 Nov;18(11):1512-1522. doi: 10.1016/S1470-2045(17)30604-6. Epub 2017 Oct 13.

PMID:
29037983
48.

The Use of PET/CT and Bone Marrow Aspiration/Biopsy in Initial Staging Evaluation of Adolescent and Adult Ewing Sarcomas.

Inagaki C, Shimoi T, Okuma H, Shimomura A, Noguchi E, Yunokawa M, Yonemori K, Shimizu C, Fujiwara Y, Tamura K.

Ann Oncol. 2017 Oct;28 Suppl 9:ix100. doi: 10.1093/annonc/mdx621.021. No abstract available.

49.

Prolonged Hypocalcemia Following a Single Dose of Denosumab for Diffuse Bone Metastasis of Gastric Cancer after Total Gastrectomy.

Iizumi S, Shimoi T, Nishikawa T, Kitano A, Sasada S, Shimomura A, Noguchi E, Yunokawa M, Yonemori K, Shimizu C, Fujiwara Y, Tamura K.

Intern Med. 2017 Nov 1;56(21):2879-2882. doi: 10.2169/internalmedicine.8908-17. Epub 2017 Sep 25.

50.

Durable complete response in HER2-positive breast cancer: a multicenter retrospective analysis.

Niikura N, Shimomura A, Fukatsu Y, Sawaki M, Ogiya R, Yasojima H, Fujisawa T, Yamamoto M, Tsuneizumi M, Kitani A, Watanabe J, Matsui A, Takahashi Y, Takashima S, Shien T, Tamura K, Saji S, Masuda N, Tokuda Y, Iwata H.

Breast Cancer Res Treat. 2018 Jan;167(1):81-87. doi: 10.1007/s10549-017-4489-9. Epub 2017 Sep 11.

PMID:
28895005

Supplemental Content

Loading ...
Support Center